Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease
Ключови думи
Резюме
Описание
Curcumin is a potent antioxidant found in extracts of the rhizome of the plant Curcuma longa L.
Different studies have demonstrated that curcumin has potent biological activity and therefore is an effective therapeutic agent for the treatment of various ailments.
This compound acts as a bifunctional antioxidant:
ه is capable of reacting directly with highly reactive oxygen species. ه acts indirectly by its ability to induce the expression of various cytoprotective proteins through Keap1/Nrf2/ARE pathway.
Although RAAS blockade is the cornerstone to prevent the progression of proteinuric nephropathy, a significant number of patients remained with proteinuria and progress to end-stage renal disease.
Due to the low cost and few side effects of curcumin, this could become an adjuvant treatment of proteinuric nephropathy purposes attenuate the progression of chronic kidney disease.
Дати
| Последна проверка: | 06/30/2014 |
| Първо изпратено: | 04/08/2013 |
| Очаквано записване подадено: | 04/09/2013 |
| Първо публикувано: | 04/14/2013 |
| Изпратена последна актуализация: | 07/22/2014 |
| Последна актуализация публикувана: | 07/23/2014 |
| Действителна начална дата на проучването: | 01/31/2013 |
| Приблизителна дата на първично завършване: | 03/31/2014 |
| Очаквана дата на завършване на проучването: | 03/31/2014 |
Състояние или заболяване
Интервенция / лечение
Drug: Curcumin
Фаза
Групи за ръце
| Arm | Интервенция / лечение |
|---|---|
| Active Comparator: Diabetic | |
| Active Comparator: Non-diabetic |
Критерии за допустимост
| Възрасти, отговарящи на условията за проучване | 18 Years Да се 18 Years |
| Полове, допустими за проучване | All |
| Приема здрави доброволци | Да |
| Критерии | Inclusion Criteria: - Diagnosis of proteinuric chronic kidney disease with 1g or more of proteins in a daily recollection. - Individuals taking Angiotensin II Receptor Blocker or ACE inhibitors in monotherapy with maximum dose or in combination. Exclusion Criteria: - Hepatic damage. - Malignancy. - Pregnancy. - Peritoneal or hemodialysis. - Organ transplantation. - Heart failure classification III or IV (New York Heart Association). - History of chemotherapy within 2 years prior to screening. |
Резултат
Първични изходни мерки
1. Change in proteinuria [8 weeks]
